drugset / Trial / NCT00947167
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
NaSingle-groupOpen-labelTreatment
Summary
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who have stable disease or progressive disease at three months (Simon design).
Timeline
- Start
- 2009-03
- Primary completion
- 2010-05
- Completion
- 2010-05
Outcome
Outcome not reported
Stopped: “Extreme toxicity of Pertuzumab and Erlotinib combination”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |